Artículos de revistas
Docosahexaenoic acid and hydroxytyrosol co-administration fully prevents liver steatosis and related parameters in mice subjected to high-fat diet: A molecular approach
Fecha
2019Registro en:
Soto‐Alarcón, S. A., Ortiz, M., Orellana, P., Echeverría, F., Bustamante, A., Espinosa, A., ... & Videla, L. A. (2019). Docosahexaenoic acid and hydroxytyrosol co‐administration fully prevents liver steatosis and related parameters in mice subjected to high‐fat diet: A molecular approach. Biofactors, 45(6), 930-943.
0951-6433
1872-8081
DOI: 10.1002/biof.1556
Autor
González-Manan, Daniel [Univ Mayor, Fac Ciencias, Nucleo Quim & Bioquim]
Soto-Alarcón, Sandra A.
Ortiz, Macarena
Orellana, Paula
Echeverria, Francisca
Bustamante, Andres
Espinosa, Alejandra
Illesca, Paola
Valenzuela, Rodrigo
Videla, Luis A.
Institución
Resumen
Attenuation of high-fat diet (HFD)-induced liver steatosis is accomplished by different nutritional interventions. Considering that the n-3 PUFA docosahexaenoic acid (DHA) modulates lipid metabolism and the antioxidant hydroxytyrosol (HT) diminishes oxidative stress underlying fatty liver, it is hypothesized that HFD-induced steatosis is suppressed by DHA and HT co-administration. Male C57BL/6J mice were fed a control diet (CD; 10% fat, 20% protein, 70% carbohydrates) or a HFD (60% fat, 20% protein, 20% carbohydrates) for 12 weeks, without and with supplementation of DHA (50 mg/kg/day), HT (5 mg/kg/day) or both. The combined DHA + HT protocol fully prevented liver steatosis and the concomitant pro-inflammatory state induced by HFD, with suppression of lipogenic and oxidative stress signaling, recovery of fatty acid oxidation capacity and enhancement in resolvin availability affording higher inflammation resolution capability. Abrogation of HFD-induced hepatic steatosis by DHA and HT co-administration represents a crucial therapeutic strategy eluding disease progression into stages lacking efficacious handling at present time.